Nippon Shinyaku | Sustainability Performance
Is a pharmaceutical company that focuses on the research, development, and marketing of innovative medicines.
1911
Japan
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5625
Overallⓘ#249
in Japanⓘ#128
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Nippon Shinyaku Co Ltd, Japanese specialty pharma (Uptravi, Viltepso), has faced multiple US FDA Form 483 observations at multiple Japanese production facilities, plus the contested 2024 sustained share price volatility amid Uptravi pulmonary hypertension competitive market displacement from generic competition affecting Japanese institutional shareholders amid Japanese specialty pharma sector consolidation pressure.
